A new drug used in a clinical investigation. The United States Food and Drug Administration’s Investigational New Drug (IND) programme is the vehicle by which a pharmaceutical company is granted permission to ship an experimental drug across state lines prior to a marketing application for the drug is approved.
See also:
Food And Drug Administration (FDA)
Drug usage/utilisation review (DUR)
License (product)




